Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

EMA Tackles Tricky Business Of Defining Therapeutic Indications

The European Medicines Agency has identified key elements that regulatory reviewers should consider when evaluating the therapeutic indications proposed by companies.

Drug Review Europe

China Joins International Post-Market Surveillance Program

China’s National Medical Products Administration says that participating in the International Medical Device Regulators Forum’s program will help it control the risks associated with imported products.

China Safety

Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster

Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.

Drug Review Europe

Hong Kong Tests Acceptance Of South Korean Device Approvals

A new trial in Hong Kong applies to class II, III and IV medical devices that are already approved by South Korea’s Ministry of Food and Drug Safety.

Approvals Hong Kong

Yet Another Myeloma CAR-T Therapy Makes It Onto EMA’s PRIME

Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.

Research and Development Strategies Europe

New Price Helps Secure Funding For Rubraca In England

Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.

Health Technology Assessment United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register